The US District Court for the Southern District of New York has ruled in favor of Teva Pharmaceutical Industries in Copaxone patent infringement litigation.
Teva filed lawsuit against Momenta/Sandoz and Mylan/Natco for infringement of multiple patents covering the chemical composition of Copaxone, methods of using the product and processes for manufacturing the product.
The decision covers several patents, the last of which expires on 1 September 2015.
Teva president and chief executive officer Jeremy Levin said, "Teva is confident COPAXONE will remain a proprietary, global market leading product for the reduction of relapses in patients with RRMS over the product's lifecycle given the strength of its intellectual property (IP) rights."
The court rejected Momenta/Sandoz and Mylan/Natco's claims that the Copaxone patents are invalid and unenforceable.
The court also found that the purported generic versions of Copaxone for which the companies seek FDA approval infringe Teva's patents.
